<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="manner" type="rst"/>
			<rel name="evidence" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="antithesis" type="rst"/>
			<rel name="condition" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">4. Discussion</segment>
<segment id="2" parent="1002" relname="span">There is little published literature</segment>
<segment id="3" parent="1003" relname="span">considering the role of palliative radiotherapy in metastatic sarcoma ,</segment>
<segment id="4" parent="1005" relname="span">although it is recommended as a treatment option for palliation by both the UK bone and soft tissue sarcoma guidelines and the European Society of Medical Oncology</segment>
<segment id="5" parent="4" relname="restatement">( ESMO )</segment>
<segment id="6" parent="1004" relname="same_unit">guidelines .</segment>
<segment id="7" parent="1008" relname="span">To the authors ’ knowledge</segment>
<segment id="8" parent="1009" relname="span">this is the largest retrospective study</segment>
<segment id="9" parent="8" relname="elaboration">published to date</segment>
<segment id="10" parent="1008" relname="elaboration">reviewing the use of palliative radiotherapy for sarcoma .</segment>
<segment id="11" parent="12" relname="attribution">The results confirm</segment>
<segment id="12" parent="1011" relname="span">that palliative radiotherapy can successfully provide symptomatic benefit to patients with metastatic sarcoma .</segment>
<segment id="13" parent="1013" relname="span">This study is limited</segment>
<segment id="14" parent="1014" relname="span">by being retrospective</segment>
<segment id="15" parent="14" relname="elaboration">such that the assessment of symptomatic improvement could only be assessed from documentation in medical records .</segment>
<segment id="16" parent="1021" relname="span">It was therefore not possible to quantify the amount of symptomatic improvement</segment>
<segment id="17" parent="16" relname="elaboration">seen</segment>
<segment id="18" parent="1020" relname="contrast">or indeed to be certain of the accuracy of the results .</segment>
<segment id="19" parent="1024" relname="attribution">The aim of this review , however , was to confirm</segment>
<segment id="20" parent="1024" relname="joint">that radiotherapy does have a role in the palliation of advanced sarcomas</segment>
<segment id="21" parent="1025" relname="span">and to guide future prospective studies</segment>
<segment id="22" parent="21" relname="purpose">to gain more accurate evidence of the use of palliative radiotherapy in this setting .</segment>
<segment id="23" parent="1026" relname="span">In addition , this study was limited by the heterogeneous population</segment>
<segment id="24" parent="23" relname="elaboration">studied .</segment>
<segment id="25" parent="1015" relname="joint">Both soft tissue and bone sarcomas of multiple types were included .</segment>
<segment id="26" parent="1029" relname="concession">The radiobiology of the different subtypes of sarcoma has not been well studied ,</segment>
<segment id="27" parent="28" relname="attribution">but it is accepted</segment>
<segment id="28" parent="1029" relname="span">that these tumours tend to be relatively radio-resistant , with a high alpha beta ratio .</segment>
<segment id="29" parent="1030" relname="span">There have been several publications</segment>
<segment id="30" parent="29" relname="elaboration">considering the role of palliative radiotherapy for other , more common solid tumour types .</segment>
<segment id="31" parent="1034" relname="attribution">A meta-analysis has shown</segment>
<segment id="32" parent="1034" relname="same_unit">that</segment>
<segment id="33" parent="34" relname="circumstance">when treating bone metastases from a number of different primary tumour sites and histology ’s ,</segment>
<segment id="34" parent="1035" relname="span">there appears to be little short-term symptomatic benefit in a fractionated course of radiotherapy , compared to a single fraction .</segment>
<segment id="35" parent="1038" relname="span">Most oncologists therefore advocate the use of a single fraction</segment>
<segment id="36" parent="35" relname="purpose">to control pain secondary to bone metastases .</segment>
<segment id="37" parent="1040" relname="attribution">With longer follow-up , however , it seems</segment>
<segment id="38" parent="1042" relname="span">that patients</segment>
<segment id="39" parent="38" relname="elaboration">treated with a fractionated course of palliative radiotherapy are less likely to need retreatment</segment>
<segment id="40" parent="1042" relname="antithesis">than those</segment>
<segment id="41" parent="1041" relname="elaboration">given a single fraction .</segment>
<segment id="42" parent="1044" relname="attribution">This study demonstrates</segment>
<segment id="43" parent="1044" relname="span">that selected patients with advanced sarcoma can benefit from palliative radiotherapy</segment>
<segment id="44" parent="1045" relname="span">provided their prognosis is long enough for the benefits from radiotherapy , in terms of symptomatic improvement ,</segment>
<segment id="45" parent="1046" relname="span">to outweigh the inconvenience</segment>
<segment id="46" parent="1047" relname="span">of undergoing radiotherapy and the associated side effects</segment>
<segment id="47" parent="46" relname="elaboration">that they may suffer .</segment>
<segment id="48" parent="1049" relname="span">As sarcomas are felt to be intrinsically radio-resistant ,</segment>
<segment id="49" parent="1051" relname="attribution">it can be hypothesized</segment>
<segment id="50" parent="1051" relname="span">that a single fraction of palliative radiotherapy may not be sufficient</segment>
<segment id="51" parent="50" relname="purpose">to offer adequate symptomatic benefit .</segment>
<segment id="52" parent="1052" relname="span">The results</segment>
<segment id="53" parent="1054" relname="span">presented here suggest a higher symptomatic response rate with a biological effective dose</segment>
<segment id="54" parent="53" relname="elaboration">( BED )</segment>
<segment id="55" parent="1054" relname="elaboration">of 50 or greater .</segment>
<segment id="56" parent="57" relname="preparation">Figure 3</segment>
<segment id="57" parent="1056" relname="span">b demonstrates an increase in response rate with increasing BED up to 50 Gy4 .</segment>
<segment id="58" parent="1058" relname="contrast">Beyond this point the response is maintained</segment>
<segment id="59" parent="1059" relname="span">but does not appear to increase further ,</segment>
<segment id="60" parent="1060" relname="span">suggesting very high doses of palliative radiotherapy may not be necessary</segment>
<segment id="61" parent="60" relname="purpose">to achieve a good symptomatic response in this patient group .</segment>
<segment id="62" parent="1062" relname="preparation">The one apparent outlier in</segment>
<segment id="63" parent="1063" relname="preparation">Figure 3</segment>
<segment id="64" parent="1064" relname="span">b is the 100 % symptomatic response in patients</segment>
<segment id="65" parent="1066" relname="condition">receiving a BED of 30 – 39.9 ,</segment>
<segment id="66" parent="1066" relname="span">this is likely to be an outlier</segment>
<segment id="67" parent="66" relname="circumstance">as there was only one patient in this group .</segment>
<segment id="68" parent="1069" relname="span">Because of the limited evidence</segment>
<segment id="69" parent="1071" relname="span">available in the use of radiotherapy for palliation in sarcoma the Royal College of Radiologists Radiotherapy dose fractionation guidance</segment>
<segment id="70" parent="69" relname="elaboration">( 3rd edition )</segment>
<segment id="71" parent="1072" relname="span">recommends several different dose fractionation schedules</segment>
<segment id="72" parent="71" relname="elaboration">( Table 5 ) .</segment>
<segment id="73" parent="1074" relname="span">Excluding 8 Gy single fraction and 20 Gy in 5 fractions</segment>
<segment id="74" parent="73" relname="elaboration">which are commonly used schedules for all solid tumours ;</segment>
<segment id="75" parent="1074" relname="elaboration">the remaining recommended dose fractionation schedules all have a BED of greater than 50 Gy4 .</segment>
<segment id="76" parent="1077" relname="attribution">Although this case series has demonstrated</segment>
<segment id="77" parent="1077" relname="span">that very high doses of radiotherapy may not provide additional short-term symptomatic benefit ,</segment>
<segment id="78" parent="1078" relname="span">longer courses of radiotherapy may be considered in patients with a good performance status and prognosis</segment>
<segment id="79" parent="1079" relname="span">in an attempt to provide a longer period of symptomatic benefit</segment>
<segment id="80" parent="79" relname="manner">without the need for retreatment .</segment>
<segment id="81" parent="1082" relname="span">A previously published case series of 17 patients</segment>
<segment id="82" parent="81" relname="elaboration">who received palliative radiotherapy for sarcoma</segment>
<segment id="83" parent="1083" relname="span">using 39 Gy in 13 fractions over two and a half weeks</segment>
<segment id="84" parent="1085" relname="attribution">demonstrated</segment>
<segment id="85" parent="1085" relname="joint">this was well tolerated</segment>
<segment id="86" parent="1085" relname="joint">and provided high rates of durable pain control .</segment>
<segment id="87" parent="1087" relname="span">Collection of survival data may help to assess</segment>
<segment id="88" parent="87" relname="condition">if the correct patients are being offered higher dose , longer courses of radiotherapy .</segment>
<segment id="89" parent="1090" relname="preparation">Figure 4</segment>
<segment id="90" parent="1090" relname="span">however does not appear to show any correlation between the BED of the radiotherapy</segment>
<segment id="91" parent="90" relname="elaboration">delivered and overall survival .</segment>
<segment id="92" parent="1091" relname="joint">Interpretation of this data is extremely limited</segment>
<segment id="93" parent="1093" relname="span">because of the heterogeneity of the patient population with multiple different histological subtypes and the small numbers of patients</segment>
<segment id="94" parent="93" relname="elaboration">treated with each dose and fractionation schedule .</segment>
<segment id="95" parent="1094" relname="span">To gain a better understanding of the most appropriate dose and fractionation schedules for different sarcoma subtypes</segment>
<segment id="96" parent="1095" relname="span">large volume , multicentre , prospective data collections is required</segment>
<segment id="97" parent="1096" relname="joint">using a small number of different dose and fractionation schedules ,</segment>
<segment id="98" parent="1098" relname="span">ideally those</segment>
<segment id="99" parent="98" relname="elaboration">outlined by the Royal College of Radiologists</segment>
<segment id="100" parent="1098" relname="evidence">( Table 5 ) .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1006" relname="background"/>
<group id="1003" type="span" parent="2" relname="elaboration"/>
<group id="1004" type="multinuc" parent="3" relname="concession"/>
<group id="1005" type="span" parent="1004" relname="same_unit"/>
<group id="1006" type="multinuc" parent="1001" relname="span"/>
<group id="1007" type="span" parent="1006" relname="joint"/>
<group id="1008" type="span" parent="1007" relname="span"/>
<group id="1009" type="span" parent="7" relname="elaboration"/>
<group id="1010" type="span" parent="1006" relname="joint"/>
<group id="1011" type="span" parent="1012" relname="preparation"/>
<group id="1012" type="span" parent="1010" relname="span"/>
<group id="1013" type="span" parent="1015" relname="preparation"/>
<group id="1014" type="span" parent="13" relname="means"/>
<group id="1015" type="multinuc" parent="1012" relname="span"/>
<group id="1019" type="span" parent="1015" relname="joint"/>
<group id="1020" type="multinuc" parent="1019" relname="span"/>
<group id="1021" type="span" parent="1020" relname="contrast"/>
<group id="1022" type="multinuc" parent="1020" relname="elaboration"/>
<group id="1023" type="span" parent="1022" relname="joint"/>
<group id="1024" type="multinuc" parent="1023" relname="span"/>
<group id="1025" type="span" parent="1024" relname="joint"/>
<group id="1026" type="span" parent="1022" relname="joint"/>
<group id="1028" type="span" parent="1015" relname="joint"/>
<group id="1029" type="span" parent="1028" relname="span"/>
<group id="1030" type="span" parent="1015" relname="joint"/>
<group id="1031" type="span" parent="1015" relname="joint"/>
<group id="1032" type="span" parent="1031" relname="span"/>
<group id="1033" type="span" parent="1032" relname="span"/>
<group id="1034" type="multinuc" parent="1033" relname="span"/>
<group id="1035" type="span" parent="1034" relname="same_unit"/>
<group id="1036" type="span" parent="1033" relname="elaboration"/>
<group id="1037" type="multinuc" parent="1036" relname="span"/>
<group id="1038" type="span" parent="1037" relname="joint"/>
<group id="1039" type="span" parent="1037" relname="joint"/>
<group id="1040" type="span" parent="1039" relname="span"/>
<group id="1041" type="span" parent="1040" relname="span"/>
<group id="1042" type="span" parent="1041" relname="span"/>
<group id="1043" type="span" parent="1037" relname="elaboration"/>
<group id="1044" type="span" parent="1043" relname="span"/>
<group id="1045" type="span" parent="43" relname="elaboration"/>
<group id="1046" type="span" parent="44" relname="purpose"/>
<group id="1047" type="span" parent="45" relname="elaboration"/>
<group id="1048" type="multinuc" parent="1032" relname="circumstance"/>
<group id="1049" type="span" parent="1048" relname="joint"/>
<group id="1050" type="span" parent="48" relname="purpose"/>
<group id="1051" type="span" parent="1050" relname="span"/>
<group id="1052" type="span" parent="1048" relname="joint"/>
<group id="1053" type="span" parent="52" relname="elaboration"/>
<group id="1054" type="span" parent="1053" relname="span"/>
<group id="1056" type="span" parent="1015" relname="joint"/>
<group id="1058" type="multinuc" parent="1015" relname="joint"/>
<group id="1059" type="span" parent="1058" relname="contrast"/>
<group id="1060" type="span" parent="59" relname="elaboration"/>
<group id="1061" type="span" parent="1015" relname="joint"/>
<group id="1062" type="span" parent="1061" relname="span"/>
<group id="1063" type="span" parent="1062" relname="span"/>
<group id="1064" type="span" parent="1063" relname="span"/>
<group id="1065" type="span" parent="64" relname="elaboration"/>
<group id="1066" type="span" parent="1065" relname="span"/>
<group id="1067" type="multinuc" parent="1064" relname="cause"/>
<group id="1068" type="span" parent="1067" relname="joint"/>
<group id="1069" type="span" parent="1068" relname="span"/>
<group id="1070" type="multinuc" parent="68" relname="elaboration"/>
<group id="1071" type="span" parent="1070" relname="same_unit"/>
<group id="1072" type="span" parent="1070" relname="same_unit"/>
<group id="1073" type="span" parent="1069" relname="evidence"/>
<group id="1074" type="span" parent="1073" relname="span"/>
<group id="1075" type="multinuc" parent="1067" relname="joint"/>
<group id="1076" type="span" parent="1075" relname="joint"/>
<group id="1077" type="span" parent="1076" relname="span"/>
<group id="1078" type="span" parent="77" relname="elaboration"/>
<group id="1079" type="span" parent="78" relname="elaboration"/>
<group id="1080" type="multinuc" parent="1075" relname="joint"/>
<group id="1081" type="span" parent="1080" relname="joint"/>
<group id="1082" type="span" parent="1081" relname="span"/>
<group id="1083" type="span" parent="1082" relname="elaboration"/>
<group id="1084" type="span" parent="83" relname="elaboration"/>
<group id="1085" type="multinuc" parent="1084" relname="span"/>
<group id="1086" type="span" parent="1080" relname="joint"/>
<group id="1087" type="span" parent="1088" relname="preparation"/>
<group id="1088" type="multinuc" parent="1086" relname="span"/>
<group id="1089" type="span" parent="1088" relname="joint"/>
<group id="1090" type="span" parent="1089" relname="span"/>
<group id="1091" type="multinuc" parent="1088" relname="joint"/>
<group id="1092" type="span" parent="1091" relname="joint"/>
<group id="1093" type="span" parent="1092" relname="span"/>
<group id="1094" type="span" parent="1093" relname="purpose"/>
<group id="1095" type="span" parent="95" relname="elaboration"/>
<group id="1096" type="multinuc" parent="96" relname="means"/>
<group id="1097" type="span" parent="1096" relname="joint"/>
<group id="1098" type="span" parent="1097" relname="span"/>
	</body>
</rst>
